lyox.com

News

Thank you for visiting us at the Forum EPFL 2022
1 January, 1970

...
LYO-X will be recruiting at the Forum EPFL 2022
3 October, 2022

Curious to learn more about LYO-X AG? Then join us at the Forum EPFL at the Swisstech Convention Center in Lausanne:

LYO-X and iBX are co-locating in the city centre of Basel!
15 September, 2022

We are excited to announce that from the 1st July 2022, Integrated Biologix GmbH is co-locating with LYO-X AG in the beautiful city centre of Basel.

...
LYO-X has moved to the center of the beautiful town of Basel
9 May, 2022

We are excited to announce that on the 1st April 2022, LYO-X has moved to the center of the beautiful town of Basel!

...
Thank you for visiting us at the Forum EPFL
22 October, 2021

...
LYO-X will be recruiting at the Forum EPFL
7 October, 2021

Come and see us in booth C15 at the SwissTech Convention Center in Lausanne.

...
Keep an eye on your target - Why increasing the half-life of your antibody is not always the solution.
22 June, 2021

...
Comprehensive mathematical model of the alternative complement pathway describing in vitro experimental- and clinical-data
5 October, 2020

We recently published a comprehensive mathematical model of the alternative complement pathway in the PLOS Computational Biology journal. Building on previous modelling efforts, in this work...

Population PK/PD Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation
5 June, 2020

Glenzocimab (ACT017) is a humanized monoclonal antigen‐binding fragment (Fab) directed against the human platelet glycoprotein VI, a key receptor for collagen and fibrin that plays a major...

Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model
17 April, 2020

Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance...

LYO-X is a consulting and modeling & simulation company specialized in PK/PD and Quantitative Systems Pharmacology for the preclinical, translational and clinical development of biologics and novel drug formats.

Antibodies
Bi-specifics
ADC's
Nanobodies
Fab Fragments
Cell
Based Therapies
PEGylated proteins
Oligonucleotides

Mission

We support the translation of innovation into pharmacological concepts and therapies. We believe that the most innovative therapeutic ideas deserve the best development tools. We use Systems Pharmacology as a key tool to maximize the success of your preclinical program, clinical study or registration.

Services

Our services includes consultancy and implementation of systems pharmacology and PK/PD modelling for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, paediatric dose selection and dose / regimen finding studies.

Why Choose us

Our methods have been successfully applied in global pharmaceutical companies with tangible results including patents. We have the unique tested expertise developing bi-specifics, antibody-drug conjugates, scFv’s, nanobodies, cell based therapies to provide tailored support for your program.

Partners

LYO-X is closely working with KinDyn Consulting and Integrated Biologix in order to provide fully integrated consultancy for preclinical and clinical development of biologics covering toxicology, pathology, CMC, bioanalysis, PK/PD, immunogenicity and regulatory strategies.

LYO-X is partnering with Lixoft to provide you access to Monolix, the scientifically and technologically most advanced software for preclinical and clinical data analysis.

News

Thank you for visiting us at the Forum EPFL 2022
1 January, 1970

...
LYO-X will be recruiting at the Forum EPFL 2022
3 October, 2022

Curious to learn more about LYO-X AG? Then join us at the Forum EPFL at the Swisstech Convention Center in Lausanne:

LYO-X and iBX are co-locating in the city centre of Basel!
15 September, 2022

We are excited to announce that from the 1st July 2022, Integrated Biologix GmbH is co-locating with LYO-X AG in the beautiful city centre of Basel.

...
LYO-X has moved to the center of the beautiful town of Basel
9 May, 2022

We are excited to announce that on the 1st April 2022, LYO-X has moved to the center of the beautiful town of Basel!

...
Thank you for visiting us at the Forum EPFL
22 October, 2021

...
LYO-X will be recruiting at the Forum EPFL
7 October, 2021

Come and see us in booth C15 at the SwissTech Convention Center in Lausanne.

...
Keep an eye on your target - Why increasing the half-life of your antibody is not always the solution.
22 June, 2021

...
Comprehensive mathematical model of the alternative complement pathway describing in vitro experimental- and clinical-data
5 October, 2020

We recently published a comprehensive mathematical model of the alternative complement pathway in the PLOS Computational Biology journal. Building on previous modelling efforts, in this work...

Population PK/PD Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation
5 June, 2020

Glenzocimab (ACT017) is a humanized monoclonal antigen‐binding fragment (Fab) directed against the human platelet glycoprotein VI, a key receptor for collagen and fibrin that plays a major...

Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model
17 April, 2020

Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance...

Systems Pharmacology An Industry Perspective

Matthias Machacek - Systems Pharmacology with Small Data

Engineering Industry Day - Lyo-X

FcRn engineered half life assessment